Sinovac H1 Revenue Jumps 13% on 82% Overseas Sales Surge
SVA is trading near its 52-week low of $5.73 (13% above the low).
Summary
Sinovac reported H1 2026 revenue of $147.08 million, up 13% year-over-year, driven by an 82% surge in overseas sales that now account for 45% of total revenue. Gross margin improved due to a shift toward higher-margin international sales and cost efficiencies. However, net loss attributable to common shareholders widened to $91.40 million, with operating expenses of $213.58 million. The company plans to submit an NDA for its PCV13 vaccine in Q3 2026 and pursue WHO prequalification for its rabies vaccine. This follows a turbulent period including a Nasdaq delisting threat and a $59.7 million net loss for 2025, making the revenue growth and margin improvement a notable positive turn.
At the time of this announcement, SVA was trading at $6.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460.3M. The 52-week trading range was $5.73 to $8.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.